Evidence map›Paper›PMID 41300507›Full record

ArticleAntioxidants (Basel, Switzerland)2025

Anti-Tumoral Treatment with Thioredoxin Reductase 1 Inhibitor Auranofin Fosters Regulatory T Cell and B16F10 Expansion in Mice.

Michael Y Bonner, Tamas Vancsik, Ana Oliveira-Coelho, Pierre Sabatier, Christian M Beusch, Kejsi Zeqiraj, Carolin Svensson, Roman A Zubarev, Elias S J Arnér, Rikard Holmdahl

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michael Y BonnerDivision of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Solna, Sweden.ORCID 0000-0002-8184-0954
Tamas VancsikDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Solna, Sweden.ORCID 0000-0001-5892-3682
Ana Oliveira-CoelhoDivision of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Solna, Sweden.ORCID 0000-0001-7783-9750
Pierre SabatierDivision of Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Solna, Sweden.ORCID 0000-0002-2734-1791
Christian M BeuschDivision of Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Solna, Sweden.ORCID 0000-0001-9100-8283
Kejsi ZeqirajDivision of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Solna, Sweden.
Carolin SvenssonDivision of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Solna, Sweden.
Roman A ZubarevDivision of Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Solna, Sweden.ORCID 0000-0001-9839-2089
Elias S J ArnérDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Solna, Sweden.ORCID 0000-0002-4807-6114
Rikard HolmdahlDivision of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Solna, Sweden.ORCID 0000-0002-4969-2576

Funding

Redox modulation - Impact on Tumor Growth and Therapeutic Anticancer EfficacyF31CA224806 · NCI · KAROLINSKA INSTITUTE · PI BONNER, MICHAEL YI · 2017 to 2022
$147k
Antioxidants (editorial board member) (editorial board member)NCI NIH HHS F31 CA224806
6 · The paper itself

Abstract

Auranofin, an FDA-approved antirheumatic drug and thioredoxin reductase 1 (TXNRD1) inhibitor, has demonstrated anti-tumoral properties, but its immunological effects are not well characterized. Here, we report that auranofin unexpectedly promotes regulatory T cell (Treg) expansion. In a B16F10 melanoma model, auranofin treatment increased lung tumor coverage, IL-10 serum levels, and FOXP3

Indexed as

antigen presenting cellsauranofinB16F10NCF1NOX2NRF2reactive oxygen speciesregulatory T cellsthioredoxin reductase 1TRi-1

Identifiers

PMID41300507
PMCPMC12649656

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.